Acelyrin Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-381.64	-64.77	-41.84
Depreciation & Amortization	0.27	0	0
Share-Based Compensation	47.32	4.05	0.23
Other Operating Activities	164.35	-0.8	36.63
Operating Cash Flow	-169.71	-61.52	-4.98
Capital Expenditures	-2.29	0	0
Acquisitions	0.01	-0.08	-25
Change in Investments	-445.46	-47.79	0
Investing Cash Flow	-447.74	-47.87	-25
Share Issuance / Repurchase	576.76	0	0.02
Other Financing Activities	-8.33	274.26	124.7
Financing Cash Flow	568.44	274.26	124.72
Net Cash Flow	-49.01	164.87	94.74
Free Cash Flow	-172	-61.52	-4.98
Free Cash Flow Per Share	-2.45	-39.50	-7.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).